31 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
consist of salaries, share-based compensation and benefits of employees, costs related to the Company’s R&D activities, including contracts … from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its R&D efforts. The Company’s
6-K
EX-99.1
OBSVF
ObsEva SA
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
” and “serving society through our employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide
6-K
EX-99.1
OBSVF
ObsEva SA
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide in the focus fields of urology
6-K
EX-99.1
OBSVF
ObsEva SA
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide in the focus fields of urology, nephrology
6-K
EX-99.1
OBSVF
ObsEva SA
22 Mar 22
Current report (foreign)
7:28am
through high-quality, innovative pharmaceutical products” and “serving society through our employees.” As a strong R&D-oriented corporation
6-K
EX-99.1
qmg va0apxkw11
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
2z89jcr kzh6w
4 Feb 22
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
4:37pm
6-K
EX-99.1
55xskasxgye
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
EX-99.1
hiigq38lj8 8s
17 Dec 21
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:15am
6-K
EX-99.1
yu6 0ol168i
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
6-K
EX-99.1
fvz650ck2vpx3cvvu
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.1
shze5aouvnd
20 May 21
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of
6:30am
6-K
EX-99.1
kxruapcyvogm
10 Dec 20
Current report (foreign)
6:03am
6-K
EX-99.1
ltu jcl8qlr
24 Nov 20
Current report (foreign)
6:03am
6-K
EX-99.1
8ucr2
6 Jul 20
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
6:18am
6-K
EX-99.1
lk1u5o9oelavjeds
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am